Exabis Library
Welcome to the e-CCO Library!
P712: Tofacitinib efficacy in patients with moderate to severe ulcerative colitis: Subgroup analyses of OCTAVE Induction 1 and 2 and OCTAVE Sustain by 5-aminosalicylates use
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P713 Effects of vedolizumab on health-related quality of life, work productivity and patient concerns in patients with ulcerative colitis and Crohn’s disease in the UK and Ireland: OCTAVO cohort 2
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P713: Gut microbiota alterations after bowel preparation amongst inflammatory bowel disease patients
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P713: Home-based vedolizumab infusions: A suitable alternative to routine hospital infusions
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P713: Long-term efficacy of endoscopic balloon dilatation using single-balloon enteroscopy in patients with Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P713: Possible explanations of the marked differences in the incidence of microscopic colitis between Denmark and Sweden
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P713: Proactive therapeutic infliximab monitoring during induction phase in inflammatory bowel disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P714 Real-world effectiveness of vedolizumab in ulcerative colitis: Week 52 results from the Swedish multi-centre, prospective, observational SVEAH UC study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P714: Comparison of intestinal microbiota profiles of faecal samples, rectal swabs and mucosal biopsies in patients with Inflammatory Bowel Disease. A multicentre, observational study.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P714: Efficacy and safety of infliximab retreatment in luminal Crohn’s disease: a multi-centre, prospective, observational cohort (REGAIN) study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P714: Mucosal healing in CD with vedolizumab versus other biologics: endoscopic outcomes during long-term routine care in a multinational observational study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P714: Vedolizumab, an adequate option in medically refractory and thiopurine-intolerant inflammatory bowel disease patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P714: Vitamin D deficiency in inflammatory bowel disease: prevalence and relation to disease activity in a cohort of patients of a Mediterranean country
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P715 The prevalence of chronic musculoskeletal pain in patients with ulcerative colitis in comparison to control subjects: A cross-sectional study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P715: Achievement and maintenance of endoscopic, histologic, and combined outcomes after extended induction in Week 10 nonresponders of ozanimod: 2-year interim analysis of the True North open-label extension study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P715: Opioid use in patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P715: Real-world tofacitinib effectiveness and safety in patients with refractory ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P715: Selective enhancement of immune cell response to opportunistic microorganisms: An innovative proposal for Inflammatory Bowel Disease from an ancient grain.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P715: Trends in emergency department visits and hospitalization rates for inflammatory bowel disease: results from a single-center in 2004, 2009 and 2014
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P716 Clinical significance of residual non-rectal inflammation in ulcerative colitis patients with clinical remission
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM